NCIt definition : A bispecific antibody directed against two immune checkpoint proteins, the inhibitory
receptor lymphocyte activation gene 3 protein (LAG3; LAG-3) and the immunosuppressive
ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274),
with potential immune checkpoint inhibitory and antineoplastic activities. FS118 is
generated by incorporating an anti-LAG-3 Fc-region with antigen binding (Fcab) into
a PD-L1-specific antibody. Upon administration, FS118 simultaneously targets and binds
to LAG3 expressed on T-cells in the tumor microenvironment (TME) and PD-L1 expressed
on tumor cells. This prevents LAG3- and PD-L1-mediated signaling, reverses T-cell
inactivation, activates the immune system and enhances cytotoxic T-lymphocyte (CTL)-mediated
anti-tumor immune responses against PD-L1-expressing tumor cells, which together lead
to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF)
negatively regulates both proliferation and activation of T-cells. Its expression
is associated with tumor-mediated immune suppression. PD-L1 is overexpressed by many
human cancer cell types. PD-L1 binding to its receptor programmed death 1 (PD-1; PDCD1;
CD279) on activated T-cells inhibits the expansion and survival of CD8-positive T-cells,
suppresses the immune system and results in immune evasion.;
Semantic type(s)